FEATURES OF OSTEOPOROTIC CHANGES AT THE REPRODUCTIVE AGE FEMALES WITH DIFFUSE TOXIC GOITER (literature review and own data)

Authors

DOI:

https://doi.org/10.21856/j-PEP.2015.4.12

Keywords:

diffuse toxic goiter, osteopenia, osteoporosis, bone mineral density

Abstract

It was shown the modern data on the study of the risk factors which contribute to the formation of osseous tissue structural and functional disorders at the diffuse toxic goiter (DTG) patients and evaluation of the bone tissue metabolism. At the surveyed reproductive age women with DTG the bone disorders set up to 57.47 % (osteopenia — 54 %, osteoporosis — 46 %). As the result of the research it was proved the necessity of densitomertic examination for DTG patients, especially T-point determination which indicates early character of osteoporotic disorders at DTG.

References

Garbuzov PI. Ocherki klinicheskoj jendokrinologii;pod red. Karachenceva JuI, Kravchun NA, Il’inoj IM, Har’kov, 2011:484-489.

Balabolkin MI, Klebanova EM, Kreminskaja VM. Fundamental’naja i klinicheskaja tireoidologija: ucheb. Posobie, Moskva, 2007: 816 p.

Valdina EA. Zabolevanija shhitovidnoj zhelezy, Sankt-Peterburg, 2006: 368 p.

Verbovaja MV. Osteoporoz i Osteopatii 2002; 1:16-19.

Kotel’nikov GP, Bulgakova SV. Osteoporoz: rukovodstvo, Moskva, 2010: 512 p.

Abel’skaja IS, Nikitina LI, Doroh EA, et al. Novye tehnologii v medicine: diagnostika, lechenie, reabilitacija: materialy nauch.-prakt. konf., Minsk, 2002;1:7-9.

Rozhinskaja LJa, Belaja ZhE. Farmateka 2010;3:39-45.

Dadan J, Zbucki R, Sawicki B. Folia Morphol 2003;62(4):443-445.

Vestergaard P, Mosekilde L. Thyroid 2003; 13:585-593.

Dedov II, Mel’nichenko GA, Belaja ZhE, et al. Problemy Jendokrinologii 2011; 1:35-45.

Osteoporoz. Diagnostika, profilaktika i lechenie; pod red. Lesnjak OM, Benevolenskoj LI, Moskva, 2010: 272 p.

Adachi JD. Mayo Clin Proc 2010; 85(9):806-813.

Hazijev VV. Lokal’nyj dozovanyj kriovplyv v likuvanni dyfuznogo toksychnogo zobu, Harkiv, 2003: 22 p.

Balabolkin MI, Vetshev PS, Petunina NA, et al. Probl Jendokrinologii 2000; 4:34.

Vetshev PS, Balabolkin MI, Petrunina NO, et al. Hirurgija 2000; 8:4-7.

Popa FL, Stanciu M, Rotaru M, et al. Osteoposis International: Seven th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Porto, 2007; 18(1):130.

Sahli H, Cheour E, Metoui L, et al. Tunis Med 2006;84(6):382-384.

Olijnyk OB, Povoroznjuk VV. Problemy Osteologii’ 2011; 14(2):13-19.

Dhanwal DK, Gupta N. J Assoc Physicians India 2011; 59:561-567.

Lewiecki EM, Miller PD, Bilezikian JP. N Engl J Med 2012; 366:1546-1547.

Yu EW, Finkelstein JS. JAMA 2012; 307:2591-2592.

Kanis JA, Oden A, McCloskey EV, et al. Osteoporos Int 2012; 23(9):2239-2256.

Povoroznjuk VV, Grigor’eva NV. Bol’. Sustavy. Pozvonochnik 2011; 2:19-28.

Interpretation and Use of FRAX® in Clinical Practice from the International Society for Clinical Densitometry and International Osteoporosis Foundation 2010: 12 p.

Downloads

Published

2015-12-03

How to Cite

Gerasimenko, L. V. (2015). FEATURES OF OSTEOPOROTIC CHANGES AT THE REPRODUCTIVE AGE FEMALES WITH DIFFUSE TOXIC GOITER (literature review and own data). Problems of Endocrine Pathology, 54(4), 105-110. https://doi.org/10.21856/j-PEP.2015.4.12